Highest-materiality recent filing
Terrence A. Duffy will become Executive Chairman effective March 1, 2027 (or later when 2026 10-K is filed); he remains CEO until then.
Q4 2025 revenue $1.8B (+20% YoY), record full-year revenue $7.1B (+35%).
CME Group Announces Pricing Changes via Special Executive Report 9676
On February 2, 2026, CME Group communicated pricing changes to clients in Special Executive Report 9676.
CME Group Inc. reports financial results for quarter ended June 30, 2025
CME Group issued a press release on July 23, 2025 reporting its financial results for the quarter ended June 30, 2025.
CME Group and S&P Global sell OSTTRA joint venture to KKR for $3.1B
Total enterprise value of $3.1 billion; proceeds split 50/50 between CME and S&P Global.
CME Group declares $2.1B annual variable dividend ($5.80/share) and $3B share repurchase program
Annual variable dividend of $5.80 per share ($2.1B total) payable Jan 16, 2025 to holders of record Dec 27, 2024.
Sean Tully, Senior Managing Director Global Head Rates & OTC Products, will retire on June 2, 2023.
Ms. Fitzpatrick will continue to serve as the Company’s President and Chief Financial Officer through the Transition Date and will then assume the role of Chief Executive Officer and be appointed to the Board and its Executive Committee on the Transition Date.
Lynne C. Fitzpatrick, the Company’s current President and Chief Financial Officer, will succeed Mr. Duffy as the Company’s Chief Executive Officer
Terrence A. Duffy, the Company’s current Chairman and Chief Executive Officer, will become the Company’s Executive Chairman
the Company announced that Ms. Julie Holzrichter has decided to step down from her role as Chief Operating Officer, a position she held since 2014.
Ms. Suzanne Sprague who has served as our Senior Managing Director & Global Head of Clearing and Post-Trade Services since February 2022 has also assumed the role of Chief Operating Officer.
Ms. Lynne Fitzpatrick has been promoted to President and Chief Financial Officer.
on July 8, 2024, Mr. Dennis notified the Company of his intent to retire from the Company’s Board of Directors, effective immediately.
Michael G. Dennis will be joining CME Group Inc. (the “CME Group” or the “Company”) as of August 5, 2024 in the role of Senior Managing Director Global Head, Fixed Income.
Under the terms of the Retirement Agreement, Mr. Pietrowicz will retire from the Company on December 31, 2023 (the “Retirement Date”).
On March 30, 2023, CME Group Inc. (“CME Group” or the “Company”) announced that Sean Tully, Senior Managing Director Global Head Rates & OTC Products, will retire from the Company as of June 2, 2023.
On February 28, 2023, CME Group Inc. (“CME Group” or the “Company”) filed a Current Report on Form 8-K announcing that John W. Pietrowicz will retire from his position as Chief Financial Officer and Ms. Fitzpatrick will assume the role effective as of April 1, 2023.
On February 28, 2023, CME Group Inc. (“CME Group” or the “Company”) filed a Current Report on Form 8-K announcing that John W. Pietrowicz will retire from his position as Chief Financial Officer and Ms. Fitzpatrick will assume the role effective as of April 1, 2023.
Max materiality 0.85 · Median 0.38 · Most common event earnings